Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Philip R Mayer"'
Autor:
David R. Friend, Justin D. Vidal, Sarah Davis, Ginger D. Constantine, Philip R. Mayer, Bridget Martell, Herman Weiss, Doorbar Martin
Publikováno v:
Journal of Pharmaceutical Sciences. 108:2677-2684
This study reports the preparation, in vitro release, pharmacokinetics, and local tolerability of novel ethylene-vinyl acetate intravaginal rings (IVRs) delivering 17β-estradiol (E2) and progesterone (P), in drug-naive ovariectomized female Dorset c
Autor:
Brian Bernick, Shelli Graham, Ginger D. Constantine, David F. Archer, Philip R Mayer, Sebastian Mirkin, James A. Simon, Harvey Kushner
Publikováno v:
Menopause (New York, N.y.)
Objective: To evaluate the pharmacokinetics of TX-004HR vaginal estradiol softgel capsules when used for treating moderate-to-severe dyspareunia in postmenopausal women with vulvar and vaginal atrophy. Methods: A substudy of the REJOICE trial (multic
Autor:
Sarah Davis, David R. Friend, Herman Weiss, Justin D. Vidal, Doorbar Martin, Philip R Mayer, Ginger D Constantine, Bridget Martell
Publikováno v:
Drug delivery and translational research. 9(5)
The objectives of this work were to evaluate the in vitro release and in vivo pharmacokinetics and local tolerability of a novel, segmented ethylene-vinyl acetate (EVA) intravaginal ring (IVR) delivering progesterone (P) in drug-naive ovariectomized
Publikováno v:
Clinical Pharmacology in Drug Development. 6:27-35
Lidocaine vaginal bioadhesive gel is being developed as a local anesthetic for use in minimally invasive outpatient gynecological procedures and was investigated in single-dose and multiple-dose studies in healthy young adult women. Lidocaine doses o
Autor:
Joan M. Korth-Bradley, Philip R. Mayer, Virginia Parks, Alain Patat, Lawrence Fleckenstein, Kyle Matschke
Publikováno v:
Clinical pharmacology in drug development. 1(1)
The antiparasitic agent moxidectin is under development for the treatment of onchocerciasis. As the first-in-human study of moxidectin used a liquid formulation but other trials used tablets, a study was performed to determine the relative bioavailab
Autor:
Geraldine M. Ferron, Jeffrey Paul, Paul J. Pockros, Richard A. Preston, Marybeth Turner, John Getsy, Robert J. Noveck, Madelyn Abell, Philip R. Mayer
Publikováno v:
Clinical Therapeutics. 23:1180-1192
Background: Patients with impaired hepatic function usually require gastric acid—suppressant therapy but are at increased risk for drug interactions and may require dosage adjustments. The proton pump inhibitor pantoprazole is rapidly absorbed and
Publikováno v:
The Journal of Clinical Pharmacology. 41:149-156
The relationship between the pharmacokinetics of pantoprazole, an irreversible proton pump inhibitor, and its effect on gastric acid secretion was evaluated in humans and rats. Pantoprazole pharmacokinetics were studied in 6 rats (5 mg/kg, i.v.) and
Autor:
James C. Ermer, Sheryl A Decleene, Laura C. Strenkoski-Nix, Philip R. Mayer, William H. Cevallos
Publikováno v:
American Journal of Health-System Pharmacy. 57:1499-1505
The pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories at three dosage strengths and oral syrup were studied. The study had an open-label, randomized, crossover design. At intervals of five to nine days, healt
Publikováno v:
Clinical therapeutics. 36(6)
Background Ethionamide sugar-coated tablets have been reformulated to film-coated tablets to improve dissolution and stability. Objective The study objective was to compare the bioavailability of the film-coated (test) and sugar-coated (reference) fo
Autor:
Philip R. Mayer
Publikováno v:
Toxicologic Pathology. 23:165-169
Drug exposure in toxicology studies is dependent on input from the drug delivery system and elimination of the drug once absorbed. Although seemingly straightforward, absorption, metabolism, and other factors require a more complex interpretation of